NKTRHealthcare · BiotechnologyThe 15 Wall Street analysts covering Nektar Therapeutics hold a median 12-month price target of $150 — +288.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (78): Analysts have, on balance, been raising their forecasts.
Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +288.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Leerink Partners | Initiates | Outperform | $130 |
| 12 Oct 2026 | UBS | Initiates | Neutral | $53 |
| 9 Oct 2026 | BTIG | Reiterates | Buy | $178 |
| 9 Oct 2026 | Raymond James | Initiates | Market Perform | — |
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $185 |
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Sept 2026 | BTIG | Reiterates | Buy | — |
| 28 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 25 Sept 2026 | BTIG | Reiterates | Buy | — |
| 25 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 23 Sept 2026 | Wedbush | Maintains | Neutral | — |
| 23 Sept 2026 | Wedbush | Maintains | Neutral | $80 → $50 |
| 16 Sept 2026 | BTIG | Reiterates | Buy | — |
| 16 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | — |
| 21 Aug 2026 | JP Morgan | Reinstates | Neutral | $65 |
| 22 July 2026 | Canaccord Genuity | Initiates | Buy | $153 |
| 22 July 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 May 2026 | Wedbush | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NKTR appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Nektar Therapeutics returned −37.4% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 8% of US stocks
Cheaper than 54% of US stocks
Cheaper than 82% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 8% of US stocks
Higher than 1% of US stocks
Higher than 26% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nektar Therapeutics has a market value of $1.3B and an enterprise value of $758.2M.
Revenue in the twelve months to 30 June 2026: $54.6M. The latest quarter shrank 9.3% year on year.
Net income over the same four quarters: −$157.1M, a −287.8% net margin.
Diluted earnings per share, trailing twelve months: $−6.70.
Free cash flow in the twelve months to 30 June 2026: −$234.0M.
Trailing P/E: −3.9×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nektar Therapeutics employs 63 people — $866K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nektar is advancing rezpeg into phase III studies for atopic dermatitis. The excerpt also cites additional autoimmune indications as potential growth opportunities amid stiff competition.
Why it matters — NKTR watchers may track rezpeg's phase III progress and the potential role of other autoimmune indications in the pipeline.
Cedar Grove Capital's Q3 2026 update reported closing several long and short positions. It also initiated a small tracking position in Zedcor Inc. while continuing due diligence.
Why it matters — The excerpt does not mention Nektar Therapeutics or an NKTR position, so it provides no company-specific update for NKTR watchers.
Nektar Therapeutics was downgraded from Strong Buy to Hold by Seeking Alpha after safety concerns emerged with REZPEG, despite positive efficacy data. The Phase 2b REZOLVE-AA study showed 63% off-treatment durability but a 91.7% injection site reaction rate, raising doubts about REZPEG's market potential in alopecia areata, though the company maintains a strong cash position sufficient to fund operations into Q3 2028.
Why it matters — NKTR watchers would care because the downgrade and injection site reaction concerns cast doubt on REZPEG's commercial viability in alopecia areata, while the strong cash runway provides some reassurance on near-term dilution risk.
Nektar Therapeutics published a transcript of its shareholder/analyst call, as covered by Seeking Alpha. The transcript provides a record of company remarks and discussions presented during the call.
Why it matters — A NKTR watcher can review the official transcript to understand the company's own commentary and details shared directly with shareholders and analysts.
Nektar Therapeutics presented new clinical and biomarker data for rezpegaldesleukin (REZPEG) at the EADV 2026 Congress, including six-month off-treatment results in severe to very severe alopecia areata showing durable hair regrowth and molecular findings from its Phase IIb atopic dermatitis program. The data support advancement into a Phase III alopecia trial.
Why it matters — A NKTR watcher would care because the positive REZPEG data help validate the drug's durability and lay the groundwork for a Phase III alopecia program, a key next step in the company's pipeline.
The 15 Wall Street analysts covering Nektar Therapeutics have a median 12-month price target of $150, with estimates ranging from $50 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Nektar Therapeutics, 11 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 46 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Nektar Therapeutics ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +288.1% from the last close, and Ticker Nerd's factor model ranks Nektar Therapeutics 46 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $192 over the next 12 months.
Nektar Therapeutics returned -37.4% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?". Nektar is advancing rezpeg into phase III studies for atopic dermatitis. The excerpt also cites additional autoimmune indications as potential growth opportunities amid stiff competition.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.
CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com
